Australia markets closed

GBS Inc. (GBS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.7392-0.0508 (-6.43%)
At close: 04:00PM EDT
0.7401 +0.00 (+0.12%)
After hours: 07:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.7900
Open0.8105
Bid0.7201 x 1100
Ask0.7900 x 1000
Day's range0.7392 - 0.8194
52-week range0.3810 - 5.1100
Volume83,270
Avg. volume649,783
Market cap11.007M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.5020
Earnings date11 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.50
  • GlobeNewswire

    GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus

    NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that the Company and the University of Newcastle in Australia have selected a site for its proprietary biosensor technology. “Maintaining momentum with our partners at the University of Newcastle has been and will remain a principal objective to generating shareholder

  • GlobeNewswire

    GBS INC. Announces Adjournment of 2022 Annual Meeting of Stockholders to July 13, 2022

    NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care (the “Company”), today announced that the Company has adjourned its 2022 Annual Meeting of Stockholders (the “Annual Meeting”) originally scheduled to be held on June 16, 2022, to July 13, 2022, at 4:00 p.m., Eastern Time, or at such other time or such other date to which the meeting

  • GlobeNewswire

    GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse

    - Intelligent Fingerprinting Limited’s commercial-stage, revenue-generating platform technology would provide an expanded product upon which to leverage the existing GBS pipelineNEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced that it has executed an exclusivity agreement with Intelligent Fingerprinting Limited (“IF